Hypoglycemic drugs with proven cardiovascular (CV) benefits are recommended for patients with type 2 diabetes and CV disease. Whether the beneficial effects extend to those at lower risk remains unclear.
Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care / Vaccaro, O.; Lucisano, G.; Masulli, M.; Bonora, E.; Del Prato, S.; Rivellese, A. A.; Giorda, C. B.; Mocarelli, P.; Squatrito, S.; Maggioni, A. P.; Riccardi, G.; Nicolucci, A.. - In: THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. - ISSN 0021-972X. - 104:8(2019), pp. 3296-3302. [10.1210/jc.2019-00361]
Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care
Vaccaro O.;Masulli M.;Rivellese A. A.;Riccardi G.;
2019
Abstract
Hypoglycemic drugs with proven cardiovascular (CV) benefits are recommended for patients with type 2 diabetes and CV disease. Whether the beneficial effects extend to those at lower risk remains unclear.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
